Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Carcinoma 3Triple Negative Breast Neoplasms 2Glioblastoma 2Squamous Cell Carcinoma of Head and Neck 1Smoldering Multiple Myeloma 1Pancreatic Neoplasms 1Neoplasms, Plasma Cell 1Neoplasms 1Neoplasm Metastasis 1Melanoma 1Lymphoma, Non-Hodgkin 1Lymphoma 1Lung Neoplasms 1Liver Neoplasms 1Glioma 1Fibrolamellar hepatocellular carcinoma 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Breast Neoplasms 1Biliary Tract Neoplasms 1

Interventions

tremelimumab 2pembrolizumab 2Nivolumab 2Carboplatin 2poly ICLC 1osimertinib 1lenvatinib 1durvalumab 1cemiplimab 1balstilimab 1Vascular Endothelial Growth Factor A 1Peptides 1Pemetrexed 1Paclitaxel 1Ipilimumab 1Docetaxel 1Blood Specimen Collection 1Antibodies, Bispecific 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Diabetes Mellitus, Insulin-Dependent, 12 × poly ICLC × 90 days × Clear all
NCT06564623 2026-05-08

Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Recruiting
25 enrolled
Gastrointestinal

Diabetes Mellitus, Insulin-Dependent, 12, Biliary Tract Neoplasms, Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡